Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004

3 references·14 citing·45 second hop

FromToDepth

this work references cited by second hop

References

2004Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis710 cited
2001Cost-Effectiveness Analysis and the Consistency of Decision Making431 cited
2000Problems With the Interpretation of Pharmacoeconomic Analyses224 cited

Cited by

2015Attributes and weights in health care priority setting: A systematic review of what counts and to what extent179 cited
2015Systematic overview of cost–effectiveness thresholds in ten countries across four continents154 cited
2010Facts, Fallacies, and Politics of Comparative Effectiveness Research: Part 2 - Implications for Interventional Pain Management124 cited
2015Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness116 cited
2018Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC—Does the Presence of an Explicit Threshold Affect the ICER Proposed?115 cited
2014Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines100 cited
2012Operationalizing Value-Based Pricing of Medicines94 cited
2011Lifetime Cost-Effectiveness of Skin Cancer Prevention through Promotion of Daily Sunscreen Use88 cited
2016The population cost-effectiveness of delivering universal and indicated school-based interventions to prevent the onset of major depression among youth in Australia85 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2014

A Think Aloud Study Comparing the Validity and Acceptability of Discrete Choice and Best Worst Scaling Methods

83 cited

2014Australian Public Preferences for the Funding of New Health Technologies63 cited

2018Cost-effectiveness thresholds: methods for setting and examples from around the world61 cited

2010Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?59 cited

2014Social values and health priority setting in Australia: An analysis applied to the context of health technology assessment58 cited